1. Scrip

Did MEI/Kyowa Kirin Beat The PI3K Tolerability Trap?

Zandelisib Shows Unexpectedly Positive Data

 
• By Alaric DeArment

PI3K-delta inhibitors have often suffered from safety and tolerability issues, but Phase II data show higher efficacy and lower discontinuation rates for zandelisib than others in the class.

Snails on the athletic track moves the finish line (By Sergey Lavrentev. Shutterstock 463225937)
MEI/Kyowa Kirin's zandelisib appears to pull ahead of other PI3K-delta inhibitors on efficacy and safety • Source: Shutterstock

New data suggest that Kyowa Kirin Co., Ltd./MEI Pharma, Inc.’s PI3K inhibitor zandelisib has better-than-expected efficacy data and a favorable safety profile that could position it as a top player in a class whose members have often suffered from safety issues.

MEI and Kyowa Kirin announced 30 November interim data from their single-arm, Phase II TIDAL study testing zandelisib as a monotherapy in relapsed/refractory follicular lymphoma (FL). The two companies announced a partnership in October 2018 to develop the drug, and in April 2020 signed a $683m deal giving Kyowa Kirin rights in most global markets, along with co-development and sharing of profits and costs in the US

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.